Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis
Current Oncology · 30.06.2025 · 32 (7) · 380
DOI: 10.3390/curroncol32070380 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Current Oncology, online erschienen am 30.06.2025. Verfasst von Haley D M Schuman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 2T8, Canada. Hauptthemen laut MEDLINE: Neoplasms, Hallucinogens, Ketamine, Psilocybin. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Cancer Society and the Alberta Cancer Foundation.
Abstract (Originalsprache)
This systematic review and meta-analysis evaluates (1) the effectiveness of psychedelic-assisted therapy (PAT) using psilocybin and ketamine for psychosocial symptoms in adults with cancer, (2) contextualizes findings with non-randomized and exploratory studies of other psychedelics, and (3) examines the role of therapeutic frameworks in shaping outcomes. We searched PubMed, Cochrane Library, PsycINFO, and EMBASE (2000–2024) for randomized controlled trials (RCTs) and non-randomized studies investigating psychedelic agents in cancer populations. Meta-analyses pooled RCTs of psilocybin or ketamine using random-effects models. Non-randomized studies were synthesized narratively. Risk of bias and evidence certainty were assessed via Cochrane ROB 2.0, NIH Before–After tool, and GRADE. Eleven placebo-controlled RCTs and four single open-label studies were included. Meta-analysis of four ketamine RCTs (n = 354) showed large, rapid effects on depression/anxiety (Hedges’ g = −1.37, 95% CI: −2.66 to −0.08; I2 = 92%). Three psilocybin RCTs (n = 101) showed a large effect of psilocybin on alleviating depression (Hedges’ g = −3.13, 95% CI: −10.04 to 3.77; I2 = 95%). MDMA and LSD trials suggested promise but lacked rigor. PAT may offer meaningful relief for cancer-related distress, though effects vary by therapeutic model and context. Oncology-specific trials are needed to standardize and scale for implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 2T8, Canada.
- Faculty of Arts, Department of Psychology, University of Calgary, Calgary, AB T2N 1N4, Canada.
ORCID-Profile: Haley D M Schuman, Raèf Mina, Hanna S W Conradi, Julie M Deleemans, Linda E Carlson
Förderung
- Canadian Cancer Society and the Alberta Cancer Foundation
Zitieren
APA
Schuman, H. D. M., Savard, C., Mina, R., Barkova, S., Conradi, H. S. W., Deleemans, J. M., & Carlson, L. E. (2025). Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis. Current Oncology, 32(7), 380. https://doi.org/10.3390/curroncol32070380
Vancouver
Schuman HDM, Savard C, Mina R, Barkova S, Conradi HSW, Deleemans JM, et al. Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis. Current Oncology. 2025;32(7):380. doi:10.3390/curroncol32070380
BibTeX
@article{Schuman2025,
author = {Schuman, Haley D M and Savard, Chantal and Mina, Raèf and Barkova, Sofia and Conradi, Hanna S W and Deleemans, Julie M and Carlson, Linda E},
title = {Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis},
journal = {Current Oncology},
year = {2025},
volume = {32},
number = {7},
pages = {380},
doi = {10.3390/curroncol32070380}
}
EUVIMED